PMID- 31701698 OWN - NLM STAT- MEDLINE DCOM- 20210608 LR - 20210608 IS - 2233-6087 (Electronic) IS - 2233-6079 (Print) IS - 2233-6079 (Linking) VI - 44 IP - 2 DP - 2020 Apr TI - Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus. PG - 248-259 LID - 10.4093/dmj.2019.0018 [doi] AB - BACKGROUND: To investigate the effects of a glucagon-like peptide-1 receptor agonist on functional brain activation in lean and obese individuals with type 2 diabetes mellitus (T2DM) in response to visual food cues. METHODS: In a randomized, single-blinded, crossover study, 15 lean and 14 obese individuals with T2DM were administered lixisenatide or normal saline subcutaneously with a 1-week washout period. We evaluated brain activation in response to pictures of high-calorie food, low-calorie food, and nonfood using functional magnetic resonance imaging and measured appetite and caloric intake in participants who were given access to an ad libitum buffet. RESULTS: Obese individuals with T2DM showed significantly greater activation of the hypothalamus, pineal gland, parietal cortex (high-calorie food vs. low-calorie food, P<0.05), orbitofrontal cortex (high-calorie food vs. nonfood, P<0.05), and visual cortex (food vs. nonfood, P<0.05) than lean individuals with T2DM. Lixisenatide injection significantly reduced the functional activation of the fusiform gyrus and lateral ventricle in obese individuals with T2DM compared with that in lean individuals with T2DM (nonfood vs. high-calorie food, P<0.05). In addition, in individuals who decreased their caloric intake after lixisenatide injection, there were significant interaction effects between group and treatment in the posterior cingulate, medial frontal cortex (high-calorie food vs. low-calorie food, P<0.05), hypothalamus, orbitofrontal cortex, and temporal lobe (food vs. nonfood, P<0.05). CONCLUSION: Brain responses to visual food cues were different in lean and obese individuals with T2DM. In addition, acute administration of lixisenatide differentially affected functional brain activation in these individuals, especially in those who decreased their caloric intake after lixisenatide injection. CI - Copyright (c) 2020 Korean Diabetes Association. FAU - Bae, Jae Hyun AU - Bae JH AUID- ORCID: 0000-0002-1384-6123 AD - Department of Medicine, Seoul National University College of Medicine, Seoul, Korea. AD - Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Choi, Hyung Jin AU - Choi HJ AUID- ORCID: 0000-0003-0593-6978 AD - Department of Anatomy, Seoul National University College of Medicine, Seoul, Korea. AD - Neuroscience Research Institute, Seoul National University, Seoul, Korea. AD - Wide River Institute of Immunology, Seoul National University, Seoul, Korea. FAU - Cho, Kang Ik Kevin AU - Cho KIK AD - Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Korea. AD - Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea. FAU - Kim, Lee Kyung AU - Kim LK AD - Department of Medicine, Seoul National University College of Medicine, Seoul, Korea. AD - Department of Internal Medicine, Cheju Halla General Hospital, Jeju, Korea. FAU - Kwon, Jun Soo AU - Kwon JS AD - Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Korea. AD - Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea. AD - Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea. FAU - Cho, Young Min AU - Cho YM AUID- ORCID: 0000-0002-2331-6126 AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ymchomd@snu.ac.kr. LA - eng GR - 2016S-1/KDA/International GR - 800-20150083/Seoul National University College of Medicine/International PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20191104 PL - Korea (South) TA - Diabetes Metab J JT - Diabetes & metabolism journal JID - 101556588 RN - 0 (Glucagon-Like Peptide-1 Receptor) RN - 0 (Hypoglycemic Agents) RN - 0 (Peptides) RN - 0 (Saline Solution) RN - 74O62BB01U (lixisenatide) SB - IM MH - Aged MH - Appetite/drug effects MH - Brain/diagnostic imaging/*physiology MH - Brain Mapping/statistics & numerical data MH - Case-Control Studies MH - Cross-Over Studies MH - Cues MH - Diabetes Mellitus, Type 2/*drug therapy/epidemiology MH - Energy Intake/drug effects MH - Female MH - Food Preferences/physiology/psychology MH - Glucagon-Like Peptide-1 Receptor/*agonists/metabolism MH - Humans MH - Hypoglycemic Agents/administration & dosage/pharmacology MH - Injections, Subcutaneous MH - Magnetic Resonance Imaging/methods MH - Male MH - Middle Aged MH - Obesity/*physiopathology MH - Peptides/administration & dosage/*pharmacology MH - Photic Stimulation/methods MH - Saline Solution/administration & dosage MH - Thinness/*physiopathology PMC - PMC7188972 OTO - NOTNLM OT - Appetite OT - Brain OT - Diabetes mellitus, type 2 OT - Energy intake OT - Functional neuroimaging OT - Glucagon-like peptide 1 OT - Lixisenatide OT - Magnetic resonance imaging OT - Obesity COIS- No potential conflict of interest relevant to this article was reported. EDAT- 2019/11/09 06:00 MHDA- 2021/06/09 06:00 PMCR- 2020/04/01 CRDT- 2019/11/09 06:00 PHST- 2019/01/22 00:00 [received] PHST- 2019/05/24 00:00 [accepted] PHST- 2019/11/09 06:00 [pubmed] PHST- 2021/06/09 06:00 [medline] PHST- 2019/11/09 06:00 [entrez] PHST- 2020/04/01 00:00 [pmc-release] AID - 43.e59 [pii] AID - 10.4093/dmj.2019.0018 [doi] PST - ppublish SO - Diabetes Metab J. 2020 Apr;44(2):248-259. doi: 10.4093/dmj.2019.0018. Epub 2019 Nov 4.